The 5th ADC Analytical Development Summit is the industry’s only dedicated technical forum focused exclusively on solving the analytical challenges unique to antibody–drug conjugate (ADC) development. Designed for analytical, bioanalytical, and CMC leaders, the summit brings together senior experts from across pharma and biotech to advance analytical rigor, deepen product understanding, and enable regulatory-ready ADC submissions as modalities grow increasingly complex.
Why Attend
- Across three content-packed days, attendees will gain practical insights to:
- Optimize physicochemical, potency, and impurity analytical methods
- Decode ADC heterogeneity and move beyond average DAR measurements
- Develop biologically relevant bioassays for next-generation ADCs
- Navigate evolving regulatory expectations and strengthen CMC strategies
- Streamline analytical method transfer to QC and CDMOs
With actionable case studies and real-world lessons, you’ll stay ahead as bispecifics, dual payloads, and novel conjugate formats progress through development pipelines.
Program Highlights
- 22+ expert speakers from leading biopharma and biotech companies
- 3 in-depth workshops on advanced ADC analytical strategies
- 4+ panel discussions addressing current technical challenges
- 12+ hours of structured networking with 80+ senior analytical scientists
Featured Speakers Include
Francis Poulin (Takeda), Melvin Flores (Sutro Biopharma), John Valliere-Douglas (Pfizer), Adrienne Wildt (AbbVie), Susan Clardy (Pyxis Oncology), and Stacey Cummins-Bitz (Eli Lilly), alongside experts from AstraZeneca, Merck, BMS, Johnson & Johnson, and more.
Download the full Event Guide to explore the complete agenda, workshops, and speaker faculty: https://ter.li/opm2ur